IXICO signs expanded scope to current contract with top 10 biopharmaceutical company

4 December 2018|Categories: Contracts|

Increasing contract value by $2.4m over the remaining term

IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, today announces that it has signed an expanded scope to a current contract with a top 10 biopharmaceutical company. Additional services will be provided, increasing the value of the contract by $2.4m over the remaining 6-year term of the agreement. As a result, the contract value has increased from $2.7m to $5.1m.

The expanded scope will see IXICO providing additional imaging services, to a significantly higher number of patients, and an increased number of participating international study sites.

Giulio Cerroni, Chief Executive of IXICO, said: “I am delighted that our client has decided to expand our involvement in this important study. We value the strength of our relationships with biopharmaceutical companies and our ability to provide them with important insights that support their efforts to bring new therapies to market. This latest increase in scope demonstrates IXICO’s ability to efficiently scale operations and adapt to changing requirements as global clinical studies progress.”


Notification of the cessation of a clinical trial

12 June 2018|Categories: Contracts|

IXICO plc (AIM: IXI), the digital technologies company serving neuroscience, has received notification from one of its  pharmaceutical clients of its decision to stop the screening, randomisation and dosing in a Phase II/III clinical study [...]


Result of General Meeting

29 May 2018|Categories: Financial|

Further to the announcement on 3 May 2018 in relation to the placing of new ordinary shares in the Company to raise £5.5 million and the despatch of a related shareholder circular, IXICO plc (AIM: [...]


Half Yearly Report to 31 March 2018

22 May 2018|Categories: Financial|

Commercially-led growth strategy delivers strong H1 performance Oversubscribed capital raise of £5.5m post the period end IXICO plc (AIM: IXI), the digital technologies company serving neuroscience, today announces its unaudited interim results for the [...]


New contract with top 10 pharmaceutical company

14 May 2018|Categories: Contracts|

Providing specialist imaging clinical trials services in Huntington’s disease IXICO plc (AIM: IXI), the digital technologies company serving neuroscience, today announced that it has signed a new contract with a top 10 pharmaceutical company, [...]

Load More Posts